These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17452812)

  • 1. Vasodilating mechanisms of levosimendan: involvement of K+ channels.
    Yildiz O
    J Pharmacol Sci; 2007 May; 104(1):1-5. PubMed ID: 17452812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties.
    Gruhn N; Nielsen-Kudsk JE; Theilgaard S; Bang L; Olesen SP; Aldershvile J
    J Cardiovasc Pharmacol; 1998 May; 31(5):741-9. PubMed ID: 9593074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M; Lehtonen L
    Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels.
    Kaheinen P; Pollesello P; Levijoki J; Haikala H
    J Cardiovasc Pharmacol; 2001 Apr; 37(4):367-74. PubMed ID: 11300649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasodilating mechanisms of levosimendan.
    Yokoshiki H; Sperelakis N
    Cardiovasc Drugs Ther; 2003 Mar; 17(2):111-3. PubMed ID: 14562823
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.
    Pathak A; Lebrin M; Vaccaro A; Senard JM; Despas F
    J Clin Pharm Ther; 2013 Oct; 38(5):341-9. PubMed ID: 23594161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potassium channel-related relaxation by levosimendan in the human internal mammary artery.
    Yildiz O; Seyrek M; Yildirim V; Demirkilic U; Nacitarhan C
    Ann Thorac Surg; 2006 May; 81(5):1715-9. PubMed ID: 16631661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes.
    Yokoshiki H; Katsube Y; Sunagawa M; Sperelakis N
    Eur J Pharmacol; 1997 Aug; 333(2-3):249-59. PubMed ID: 9314042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties.
    Lehtonen LA
    Expert Opin Investig Drugs; 2001 May; 10(5):955-70. PubMed ID: 11322869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levosimendan is a mitochondrial K(ATP) channel opener.
    Kopustinskiene DM; Pollesello P; Saris NE
    Eur J Pharmacol; 2001 Oct; 428(3):311-4. PubMed ID: 11689188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levosimendan, a new inotropic and vasodilator agent.
    Toller WG; Stranz C
    Anesthesiology; 2006 Mar; 104(3):556-69. PubMed ID: 16508404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potassium channels in the vasodilating action of levosimendan on the human umbilical artery.
    Yildiz O; Nacitarhan C; Seyrek M
    J Soc Gynecol Investig; 2006 May; 13(4):312-5. PubMed ID: 16697949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial K(ATP) channel.
    Grossini E; Molinari C; Caimmi PP; Uberti F; Vacca G
    Br J Pharmacol; 2009 Jan; 156(2):250-61. PubMed ID: 19154424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of potassium channels in the vasodilatory effect of levosimendan in human internal thoracic arteries.
    Usta C; Eksert B; Gölbasi I; Bigat Z; Ozdem SS
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):329-32. PubMed ID: 16829109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein.
    Pataricza J; Hõhn J; Petri A; Balogh A; Papp JG
    J Pharm Pharmacol; 2000 Feb; 52(2):213-7. PubMed ID: 10714952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles.
    Erdei N; Papp Z; Pollesello P; Edes I; Bagi Z
    Br J Pharmacol; 2006 Jul; 148(5):696-702. PubMed ID: 16715115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levosimendan interacts with potassium channel blockers in human saphenous veins.
    Höhn J; Pataricza J; Petri A; Tóth GK; Balogh A; Varró A; Papp JG
    Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):271-3. PubMed ID: 15228498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan.
    Papp Z; Csapó K; Pollesello P; Haikala H; Edes I
    Cardiovasc Drug Rev; 2005; 23(1):71-98. PubMed ID: 15867949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levosimendan-induced venodilation is mediated by opening of potassium channels.
    Burkhoff D; Rich S; Pollesello P; Papp Z
    ESC Heart Fail; 2021 Dec; 8(6):4454-4464. PubMed ID: 34716759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.